- Report
- December 2022
- 112 Pages
Europe
From €1345EUR$1,500USD£1,165GBP
- Report
- February 2025
- 180 Pages
Global
From €4348EUR$4,850USD£3,767GBP
- Report
- August 2023
- 1300 Pages
Global
From €7978EUR$8,900USD£6,913GBP
- Report
- March 2025
- 150 Pages
Global
From €4348EUR$4,850USD£3,767GBP
- Report
- March 2025
- 150 Pages
Global
From €4348EUR$4,850USD£3,767GBP
- Report
- March 2025
- 150 Pages
Global
From €4348EUR$4,850USD£3,767GBP
- Report
- March 2025
- 150 Pages
Global
From €4348EUR$4,850USD£3,767GBP
- Report
- November 2024
- 150 Pages
Global
From €4348EUR$4,850USD£3,767GBP
- Report
- September 2024
- 150 Pages
Global
From €4348EUR$4,850USD£3,767GBP
- Report
- September 2024
- 150 Pages
Global
From €4348EUR$4,850USD£3,767GBP
- Report
- October 2025
- 90 Pages
Bahrain
From €4348EUR$4,850USD£3,767GBP
- Report
- October 2025
- 88 Pages
Saudi Arabia
From €4348EUR$4,850USD£3,767GBP
- Report
- October 2025
- 96 Pages
Saudi Arabia
From €4348EUR$4,850USD£3,767GBP
- Report
- October 2025
- 82 Pages
Qatar
From €4348EUR$4,850USD£3,767GBP
- Report
- October 2025
- 90 Pages
Kuwait
From €4348EUR$4,850USD£3,767GBP
- Report
- October 2025
- 90 Pages
Kuwait
From €4348EUR$4,850USD£3,767GBP
From €4348EUR$4,850USD£3,767GBP
- Report
- October 2025
- 95 Pages
Turkey
From €4348EUR$4,850USD£3,767GBP
- Report
- October 2025
- 87 Pages
South Korea
From €4348EUR$4,850USD£3,767GBP
- Report
- October 2025
- 94 Pages
India
From €4348EUR$4,850USD£3,767GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more